NCT06218914 - Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 22, 2024

Primary Completion Date

August 30, 2027

Study Completion Date

April 15, 2044

Conditions

Non-small Cell Lung CancerColorectal CarcinomaPancreatic Ductal AdenocarcinomaEndometrial CancerSolid Tumor, AdultKRAS G12D

Interventions

BIOLOGICAL

NT-112: Autologous, engineered T Cells targeting KRAS G12D

NT-112 targets KRAS G12D in the context of HLA-C\*08:02

BIOLOGICAL

AZD0240: Autologous, engineered T Cells targeting KRAS G12D

AZD0240 targets KRAS G12D in the context of HLA-A\*11:01 or HLA-A\*11:02

Trial Locations (17)

10016

RECRUITING

Research Site, New York

15237

RECRUITING

Research Site, Pittsburgh

19107

RECRUITING

Research Site, Philadelphia

32224

NOT_YET_RECRUITING

Research Site, Jacksonville

33136

WITHDRAWN

Research Site, Miami

37203

RECRUITING

Research Site, Nashville

53226

RECRUITING

Research Site, Milwaukee

60637

RECRUITING

Research Site, Chicago

63110

RECRUITING

Research Site, St Louis

66205

RECRUITING

Research Site, Westwood

75246

RECRUITING

Research Site, Dallas

77030

RECRUITING

Research Site, Houston

77555

RECRUITING

Research Site, Galveston

90095

RECRUITING

Research Site, Los Angeles

91010

RECRUITING

Research Site, Duarte

92663

RECRUITING

Research Site, Newport Beach

98520

RECRUITING

Research Site, Aberdeen